Overexpression of ARID4B predicts poor survival in patients with hepatocellular carcinoma

Publication date: Available online 27 December 2017
Source:Human Pathology
Author(s): Rongchang Wang, Zheng Yu, Fan Chen, Chunlian Liao, Qian Wang, Xiaohui Huang
AT-rich interaction domain 4B (ARID4B), which belongs to the ARID family, is heavily involved in cell growth and differentiation and is closely associated with many types of tumors. However, the role of this protein in hepatocellular carcinoma (HCC) remains unknown. In this study, we used data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to analyze ARID4B expression in HCC. We subjected 15 pairs of fresh-frozen tissue samples to quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting analyses to investigate ARID4B expression. We also subjected 157 formalin-fixed, paraffin-embedded (FFPE) HCC tissue samples to immunohistochemical analysis to detect ARID4B expression and to determine the clinical significance of ARID4B expression in HCC. The bioinformatics analysis, qRT-PCR and western blotting results showed that ARID4B was highly expressed in HCC tissues compared with adjacent normal liver tissues. High ARID4B expression was strongly correlated with tumor number (P = 0.02), vascular invasion (P = 0.004), Edmondson-Steiner grades (P = 0.000) and TNM stages (P = 0.001). Moreover, Kaplan-Meier and Cox proportional hazards analyses indicated that high ARID4B expression was significantly associated with poor survival in patients with HCC and that ARID4B was an independent prognostic factor for overall survival and disease-free survival in patients with HCC. In conclusion, our results suggest that ARID4B acts as an oncogene in HCC and can therefore serve as a biomarker for the prognoses of patients with HCC.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2E29Vyu